Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for EIK1005 in MSI-high / dMMR advanced solid tumors. The expected timing is based on the latest available company guidance and may change.
05/11/26:- WRN inhibitor EIK1005 Ph1/2 underway in advanced solid tumors, including MSI-H/dMMR tumors; first patient dosed in Feb 2026. 07/20/26:- ESMO 2026 to present initial safety, tolerability, and pharmacokinetics analyses for EIK1005. 08/13/26:- Initial Ph1/2 safety, tolerability, and pharmacokinetic data will be presented October 23, 2026. The trial first dosed a patient in January 2026.
Verification
Confirm timing and program details against the company announcement or filing.